Real-World Patterns of Discontinuation and Virologic Failure with Long-Acting Cabotegravir–Rilpivirine
AIDS Research and Human Retroviruses · 01.07.2026 · 42 (6-7) · 227-229
DOI: 10.1177/08892229261449867 ↗Kurz gefasst
Fachartikel in der Zeitschrift AIDS Research and Human Retroviruses, online erschienen am 05.05.2026. Verfasst von Sara Hockney und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Anti-HIV Agents, Rilpivirine. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Long-acting injectable cabotegravir–rilpivirine (LA CAB/RPV) is an antiretroviral option for virologically suppressed people with HIV, but real-world discontinuation and failure patterns remain incompletely described. We retrospectively reviewed 201 adults who received LA CAB/RPV at a large academic infectious diseases clinic (January 2022–April 2025). Median time on therapy was 380 days (IQR 206–729). At the end of follow-up, 160 (80%) remained on LA CAB/RPV and 30 (15%) discontinued, most commonly due to insurance barriers ( n = 8, 27%); adherence issues and patient preference each accounted for 23% ( n = 7). Virologic failure occurred in 4 patients (2%) and was often accompanied by emergent or pre-existing non-nucleoside reverse transcriptase inhibitor and/or integrase strand transfer inhibitor resistance mutations; all patients achieved resuppression after switching back to oral ART. LA CAB/RPV was generally well tolerated, but system-level access and care-continuity barriers were major drivers of discontinuation, underscoring the importance of robust support systems and resistance-informed patient selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Northwestern University, Chicago, Illinois, USA.
- Southwest Infectious Disease and Internal Medicine, Palos Heights, Illinois, USA.
ORCID-Profile: Sara Hockney
Zitieren
APA
Hockney, S., Mueller, D., Phillbrick, A., Berlet, J., & Galvin, S. (2026). Real-World Patterns of Discontinuation and Virologic Failure with Long-Acting Cabotegravir–Rilpivirine. AIDS Research and Human Retroviruses, 42(6-7), 227-229. https://doi.org/10.1177/08892229261449867
Vancouver
Hockney S, Mueller D, Phillbrick A, Berlet J, Galvin S. Real-World Patterns of Discontinuation and Virologic Failure with Long-Acting Cabotegravir–Rilpivirine. AIDS Research and Human Retroviruses. 2026;42(6-7):227-229. doi:10.1177/08892229261449867
BibTeX
@article{Hockney2026,
author = {Hockney, Sara and Mueller, Dana and Phillbrick, Alex and Berlet, Jenna and Galvin, Shannon},
title = {Real-World Patterns of Discontinuation and Virologic Failure with Long-Acting Cabotegravir–Rilpivirine},
journal = {AIDS Research and Human Retroviruses},
year = {2026},
volume = {42},
number = {6-7},
pages = {227--229},
doi = {10.1177/08892229261449867}
}
EUVIMED